Ravasio, Roberto, Holly Cranmer, Izzie Kearns, Raffaella Viti, and Simone Corinti. 2022. “Cost-Utility Analysis of Brigatinib Compared to Alectinib in the Treatment of ALK-Positive NSCLC in Patients Previously Not Treated With an ALK Inhibitor”. AboutOpen 9 (1):92-104. https://doi.org/10.33393/ao.2022.2450.